{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Dyspnea (shortness of breath)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Lymphopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hypoxia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Syncope (fainting)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"pulmonary/upper respiratory- other, acute respiratory event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Thrombosis/thrombus/embolism"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Encephalopathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pericardial effusion"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pain - Chest wall"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Ascites (non-malignant)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Edema: trunk/genital"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Supraventricular and nodal arrhythmia - Atrial fibrillation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Number of participants with grade 3 or grade 4 for each type of toxicity encountered, using all toxicity evaluable patients.","groups":[{"description":"Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nNintedanib: Given PO","id":"OG000","title":"Treatment (Nintedanib)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Incidence of Grade 3-4 Toxicity","type":"SECONDARY","unitOfMeasure":"Participants"}